bluebird bio, Inc. (BLUE) |
|
7.59 0.07 (0.93%)
|
11-25 13:00 |
|
Open: |
7.41 |
Pre. Close: |
7.52 |
|
High:
|
7.61 |
Low:
|
7.24 |
|
Volume:
|
1,006,982 |
Market Cap:
|
629(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 1:55:35 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 9.5 One year: 11.1 |
| Support: |
Support1: 6.53 Support2: 5.55 |
| Resistance: |
Resistance1: 8.14 Resistance2: 9.5 |
| Pivot: |
7.1  |
| Moving Average: |
MA(5): 7.17 MA(20): 6.89
MA(100): 6.09 MA(250): 5.95  |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 67.5 %D(3): 55.6 |
| RSI: |
RSI(14): 58.7 |
| 52-week: |
High: 11.69 Low: 2.86 |
| Average Vol(K): |
3-Month: 5,977 (K) 10-Days: 3,258 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BLUE ] has closed below upper band by 24.3%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.71 - 7.75 |
7.75 - 7.78 |
|
Low:
|
7.06 - 7.1 |
7.1 - 7.14 |
|
Close:
|
7.45 - 7.52 |
7.52 - 7.58 |
|
Company Description |
|
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Sat, 26 Nov 2022
Eagles Edge Blue Hose in Tight Non-Conference Battle - Presbyterian College
Sat, 26 Nov 2022
Blue Jays' needs entering 2023 - MLB.com
Sat, 26 Nov 2022
Blue Devils Welcome Panthers For NCAA Tournament Third Round Matchup - Duke University - GoDuke.com
Sat, 26 Nov 2022
'Blue Rush' Podcast Episode 126: Will Giants End Up Making The Playoffs? - New York Post
Sat, 26 Nov 2022
UPDATED: Wildcats top Blue Devils after shootout | News, Sports, Jobs - Alpena News
Sat, 26 Nov 2022
Buy the Sky Blue Samsung Galaxy S22 Ultra before it's too late - Android Police
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
83 (M) |
|
% Held by Insiders
|
7.586e+007 (%) |
|
% Held by Institutions
|
1.1 (%) |
|
Shares Short
|
22,710 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.4638e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-8 |
|
Return on Assets (ttm)
|
526.2 |
|
Return on Equity (ttm)
|
-29.5 |
|
Qtrly Rev. Growth
|
5.14e+006 |
|
Gross Profit (p.s.)
|
-94.9 |
|
Sales Per Share
|
-85.48 |
|
EBITDA (p.s.)
|
-3.58306e+008 |
|
Qtrly Earnings Growth
|
-10.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-436 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.09 |
|
Price to Cash Flow
|
3.87 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.254e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
